Canadian Bacterial Surveillance Network. March 2006.
2.
CiproDex Otic [package insert]. Fort Worth, Tex.: Alcon Laboratories; 2004.
3.
PickerillKE, PaladinoJA, SchentagJJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy2000;20(4):417–28.
4.
ForrestA, NixDE, BallowCH, Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother1993;37(5):1073–81.
5.
ThomasJK, ForrestA, BhavnaniSM, Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother1998;42(3):521–7.
6.
PongA, ThomsonKS, MolandES, Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother1999;44(5):621–7.
7.
WagnerRS, AbelsonMB, ShapiroA, TorkildsenG.Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol2005;123(9):1282–3.
8.
RusinkoA, MayJ, LiaoJ, A study of the enhanced corneal penetration of moxifloxacin [abstract 4907/B231]. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology; April 25–29, 2004; Ft. Lauderdale, Fla.
